How Is Ki-67 Interpreted in Upper-Outer Breast Cancer?

Your Ki-67 score provides a useful estimate of the proportion of your breast cancer cells that are actively dividing, but it is an indirect prognostic marker and should not single-handedly dictate your treatment plan ^[1]. Because results can vary depending on exactly how the laboratory performs the test, the score is most valuable when your care team views it alongside the other features of your cancer, such as stage, tumor grade, and hormone receptor status ^[2][3].

What Ki-67 Actually Measures

Ki-67 is a protein found inside the nucleus of cells during active phases of the cell cycle. The Ki-67 index is the percentage of cancer cells in your tissue sample that test positive for this protein ^[4]. Rather than measuring a direct speedometer of “how fast” a tumor is growing, it estimates the proportion of cells showing proliferative activity (actively dividing) at the time of testing ^[4]. A higher percentage indicates that a larger portion of the tumor cells are in the active cell cycle ^[4]. Note that having your tumor located in the upper-outer quadrant of the breast does not change what Ki-67 measures or how it is interpreted.

Why the Exact Number Can Vary

It is common for patients to worry about the exact Ki-67 percentage on their pathology report, but this number can fluctuate based on several factors:

• Laboratory differences: Different labs use slightly different chemicals (antibodies) and equipment platforms to stain the tissue, which can lead to different results ^[5].
• Scoring methods: Some pathologists count the dividing cells only in the most active area of the tumor (called hotspot scoring), while others calculate an average across the entire sample ^[6].
• Tissue sampling: A sample taken during a needle core biopsy might capture a different mix of cells than the larger tissue sample removed during surgery ^[7].

Because of this variability, experts caution against making major treatment choices based on small differences in Ki-67 scores. While there is good agreement among labs at the extreme high and low ends, results can be inconsistent when the score falls in the “intermediate” range ^[1]. An intermediate result usually cannot settle a treatment decision and may prompt your team to rely more heavily on your complete pathology picture or consider a genomic assay.

How Ki-67 Fits Into Your Care

Ki-67 interpretation differs depending on the subtype and stage of your breast cancer. It is most commonly discussed in the context of HR-positive (hormone-receptor-positive, meaning the cancer cells have receptors for estrogen and/or progesterone) and HER2-negative (lacking high levels of the HER2 protein) early-stage breast cancer.

In this specific setting, the International Ki-67 Working Group considers scores of 5% or less to be low, and scores of 30% or more to be high ^[1]. These thresholds are not universal for every breast cancer subtype. When standardized testing is used in early HR-positive/HER2-negative disease, Ki-67 can help predict prognosis—what the cancer may do over time and your expected outlook ^[1][8].

However, there is an important difference between prognosis and predicting treatment benefit. Knowing that a tumor has a higher proportion of dividing cells does not reliably predict an individual’s outcome, nor does it prove that chemotherapy will be beneficial ^[9]. For many HR-positive cancers, hormone-blocking therapy (endocrine therapy) is recommended, and the decision is whether chemotherapy should be added to it. Ki-67 alone cannot answer that question ^[10].

Ki-67 vs. Other Important Tests

Ki-67 is just one piece of your pathology report. To make the best decisions, your doctor will interpret it alongside:

• Tumor Grade: Grade looks at how abnormal the cells appear under a microscope, while Ki-67 looks at the proportion of dividing cells. They provide different but complementary information ^[3].
• Stage and Receptors: The physical size of the tumor, whether it has spread to lymph nodes or distant parts of the body (stage), and its estrogen, progesterone, and HER2 receptor status remain critical factors for guiding your care ^[2].
• Genomic Assays: Tests like Oncotype DX and MammaPrint are multigene tests that analyze the activity of multiple genes to assess your risk of recurrence. A Ki-67 score is not interchangeable with a genomic test; the two types of tests only match up modestly well ^[11]. For selected patients with early-stage HR-positive, HER2-negative breast cancer, clinical guidelines recommend using validated multigene assays to help estimate recurrence risk and whether adding chemotherapy would be beneficial ^[12]. Ki-67 may be considered in some settings when genomic testing is not available, but they do not serve the exact same purpose ^[12].